Open AccessDetermining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease
Author(s) -
Amanda L Elchynski,
Emily Cicali,
M Castineira Busto,
Alessandra Hamilton,
Ku-Lang Chang,
Siegfried Schmidt,
Brian Weiner,
Richard H. Davis,
David Estores,
D. Max Smith,
Kristin Wiisanen,
Julie A. Johnson,
Larisa H. Cavallari
Publication year - 2021
Publication title -
pharmacogenomics journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.804
H-Index - 85
eISSN - 1473-1150
pISSN - 1470-269X
DOI - 10.1038/s41397-021-00244-6
Subject(s) - gerd , medicine , pharmacogenetics , cyp2c19 , cohort , chronic pain , reflux , disease , physical therapy , genotype , biochemistry , chemistry , cytochrome p450 , metabolism , gene
We aimed to determine the potential value of panel-based pharmacogenetic (PGx) testing in patients with chronic pain or gastroesophageal reflux disease (GERD) who underwent single-gene PGx testing to guide opioid or proton pump inhibitor (PPI) therapy, respectively. Of 448 patients included (chronic pain, n = 337; GERD, n = 111), mean age was 57 years, 68% were female, and 73% were white. Excluding opiates for the pain cohort and PPIs for the GERD cohort, 76.6% of patients with pain and 71.2% with GERD were prescribed at least one additional medication with a high level of PGx evidence, most commonly ondansetron or selective serotonin reuptake inhibitors. The most common genes that could inform PGx drug prescribing were CYP2C19, CYP2D6, CYP2C9, and SLCO1B1. Our findings suggest that patients with chronic pain or GERD are commonly prescribed drugs with a high level of evidence for a PGx-guided approach, supporting panel-based testing in these populations.